7th Annual Cedars-Sinai Gastrointestinal Tumor Conference: Health System Retreat

The 7th Annual Cedars-Sinai Gastrointestinal Tumor Conference will provide concise and comprehensive updates on the most recent research and advances in therapy for gastrointestinal cancers. A stellar faculty has been assembled to share developments in precision medicine, research, and immunotherapeutic approaches. Join your colleagues for this important half day educational activity that will enhance your understanding of GI cancers and provide you with valuable information to inform your clinical decision-making and treatment approaches for your patients.

This is an invitation-only conference intended for individuals affiliated with the Cedars-Sinai Health System.

1. Analyze advances in biomarkers and therapies to evaluate and synthesize treatment options for patients with gastroesophageal cancers.
2. Use AJCC or other appropriate staging in clinical practice, including the use of appropriate prognostic indicators and evidence based national guidelines for treatment planning
3. Evaluate the basic science of immune therapy for GI malignancies and the implications for transfer from bench to bedside
4. Increase knowledge of therapy for neuroendocrine tumors and biomarker identification of novel therapies
5. Identify and implement optimal strategies for managing therapy related side effects and toxicities in patients treated with therapeutic agents
6. Anticipate the needs, problems, and issues of cancer survivors and develop an individualized wellness plan in partnership with cancer survivors, their families and the healthcare team

Cedars-Sinai Employees & Affiliates Healthcare Professional Fee (In-Person) - $0.00

This is an invitation-only conference intended for individuals affiliated with the Cedars-Sinai Health System.

Refund Policy
All cancellations must be submitted in writing and refunds will be subject to an administrative charge. To view the policy, click here. Please e-mail cancellation request to [email protected]. If you do not receive confirmation of your cancellation via e-mail, please call (310) 423-5548.

Disclaimer
All educational materials provided during and after the course are for your personal use only and should not be reproduced or distributed in any manner without the express permission of Cedars-Sinai.

Right to Cancel or Postpone
Cedars-Sinai reserves the right to cancel or postpone any course due to unforeseen circumstances. In the unlikely event that Cedars-Sinai must cancel or postpone this course, the registration fee will be fully refunded. Cedars-Sinai is not responsible for any related costs, charges or expenses to participants, including fees assessed by airline, travel or lodging agencies.

Health and Safety Protocols
As you know, the health and safety of our community are always our top priorities at Cedars-Sinai. Participants in any event should be thoughtful about their individual risks and consider avoiding public gatherings if they are of higher risk.

Click here to review the current in-person Cedars-Sinai CME Event Protocols.

In support of improving patient care, Cedars-Sinai is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement
Cedars-Sinai designates this Live Activity for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Non-Physician AMA Attendance
Attendance credit will be provided to other healthcare professionals upon the fulfillment of attendance requirements. Participants should ensure in advance that their credentialing or licensing organization accepts AMA PRA Category 1 Credits™.  

Mitigation of Relevant Financial Relationships

Cedars-Sinai adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Jun Gong, MD
Cedars-Sinai

Course Director, Faculty

Advisor-Agenus (Relationship has ended)|Advisor-AstraZeneca (Relationship has ended)|Advisor-BeOne (Relationship has ended)|Advisor-Exelixis (Relationship has ended)|Advisor-Caper Labs (Relationship has ended)|Advisor-Natera (Relationship has ended)|Advisor-Bayer Corporation (Relationship has ended)|Advisor-Genentech (Relationship has ended)|Advisor-Incyte (Relationship has ended)|Advisor-Eisai, Inc. (Relationship has ended)|Advisor-Taiho Pharmaceutical (Relationship has ended)|Advisor-Seagen (Relationship has ended)

Andrew E. Hendifar, MD
Cedars-Sinai

Course Director, Faculty

Consultant-Ipsen (Relationship has ended)|Consultant-Exelexis|Advisor-Ipsen|Consultant-Amgen|Advisor-Merck and Company, Inc. (Relationship has ended)

Arsen Osipov, MD
Cedars-Sinai

Course Director, Faculty

Advisor-Ipsen (Relationship has ended)|Advisor-Novocure (Relationship has ended)

Katelyn Atkins, MD, PhD
Cedars-Sinai

Faculty

PrincipalNamedInvestigator-Varian Medical Systems |Consultant-Revolution Medicines-Honoraria (Relationship has ended)

Miguel Burch, MD
Cedars-Sinai

Faculty

Nothing to disclose

Fahima Dossa, MD, PhD
Memorial Sloan Kettering Cancer Center
Canada

Faculty

Nothing to disclose

Cristina Ferrone, MD, FACS
Cedars-Sinai

Faculty

Nothing to disclose

Erwin Grussie, MD, PhD

Faculty

David Hoffman, MD
Cedars-Sinai

Faculty

Mitchell Kamrava, MD
Cedars Sinai

Faculty

Advisor-Alessa (Relationship has ended)|Royalties or Patent Beneficiary-Springer book rotyalties|Other: DSMB-GT Medical|Other: DSMB-Alessa

Howard S Kaufman, MD
Huntington Hospital

Faculty

Kambiz Kosari, MD
Cedars-Sinai Comprehensive Transplant Center

Faculty

Nothing to disclose

Brent K. Larson, DO
Department of Pathology and Laboratory Medicine

Faculty

Consultant-Revolution Medicines (Relationship has ended)

Pareen Mehta, MD

Faculty

Nicholas Nissen, MD
Cedars-Sinai

Faculty

Nothing to disclose

Lawrence Piro, MD
The Angeles Clinic and Research Institute

Faculty

Swati Sikaria, MD
TMMC

Faculty

Peter Slavin, MD
Cedars-Sinai Medical Center

Faculty

Nothing to disclose

Louise E J Thomson, MD
Cedars Sinai Imaging

Faculty

Nothing to disclose

Eric Vail, MD
Cedars-Sinai

Faculty

Speaker-Bayer Corporation|Consultant-Bristol-Myers Squibb|Consultant-AbbVie|Speaker-Pfizer, Inc.|Consultant-Sanofi-Aventis|Speaker-Eli Lilly and Company|Speaker-Johnson and Johnson|Speaker-AstraZeneca|Consultant-PierianDx (Relationship has ended)|Consultant-Thermo Fisher Scientific|Consultant-Illumina|Consultant-Tempus|Consultant-Caris|Independent ContractorResearcher-LungLifeAI (Relationship has ended)

Ashley Wachsman, MD
Cedars-Sinai Imaging

Faculty

Kevin M Waters, MD, PhD
Cedars-Sinai

Faculty

Consultant-Pfizer, Inc. (Relationship has ended)|Consultant-Astellas|Consultant-GlaxoSmithKline|Consultant-Gilead (Relationship has ended)

Thursday, April 16, 2026